Pharmaceutical Industry Information Portal

HomeDiscovery and Development

Discovery and Development

Bharat Biotech’s vaccine Covaxin shows that it is 77.8% efficacy

The vaccine is produced with Bharat Biotech's in-house vero cell manufacturing platform that has the capacity to deliver about 300 million doses.

COVID-19 dual-antibody therapies prevent emergence of drug resistance

Administration of antibody therapies bypasses the body’s slower and sometimes less effective process of making its own antibodies.

Cuban Soberana 02 vaccine against the coronavirus shows 62% efficacy

Vérez described the result as “very comforting,” because it has been obtained in a scenario of circulation “of the most worrying variants due to their transmissibility.”

Eisai and BMS Enter Into Strategic Collaboration for MORAb-202 Antibody Drug Conjugate

Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.

Positive results were obtained for the drug Zanubrutinib in a comparative trial with Isrutinib

Brukinsa® (zanubrutinib) is under regulatory review for relapsed, refractory MCL in the Russian Federation with potential approval at the end of the 2021.

CureVac COVID-19 vaccine proved only 47% effective – CureVac shares fell by as much as 52%

CureVac shares fell by as much as 52% on Thursday after the German biotech’s COVID-19 vaccine proved only 47% effective in an initial trial,...
spot_img

Expert Articles

spot_img